Ramaswamy Veena
SRL LAB, Fortis Hospital, No 154/9, Opposite IIM-B, Bannerghatta Road, Bangalore, 560076 India.
Indian J Surg Oncol. 2016 Jun;7(2):258-67. doi: 10.1007/s13193-016-0516-2. Epub 2016 Mar 19.
Neoplasms of the appendix are rare, but because of their unusual presentation and unpredictable biologic behavior, it is important to diagnose them correctly. Mucinous tumors account for 58 % of malignant tumors of appendix in SEER database and the remaining are carcinoids. The mucinous appendiceal tumors have a potential to spread to the peritoneum and viscera in the form of gelatinous material with or without neoplastic cells resulting in Pseudomyxoma peritonei. (PMP) PMP is a clinical entity that has a unique biological behavior and can arise from seemingly benign tumors to frankly malignant ones. Several classifications exist for PMP of which Ronnet's classification has been the most popular. In 2010, the WHO proposed a 2 tier classification that classified PMP as either low grade or high grade based on the presence of mucin, cytological and architectural features. According to this classification when the underlying cause for PMP is an appendiceal tumor it is always a mucinous adenocarcinoma rather than a mucocoele or adenoma and these terms should no longer be used. This system of classification helps in predicting the behavior of the tumor and proper treatment strategies. The understanding of the pathogenesis of the disease has also improved with identification of newer biomarkers and molecular genetic alterations. IHC markers CK 20, CDX2 and MUC2 are found to be positive in these tumors in addition to KRAS mutation and loss of heterozygosity in some gene loci. Proper histopathologic classification and predicting the tumor behavior requires a close interaction between the pathologist and the surgeon. The use of the combined modality treatment of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has led to a 5-year survival ranging from 62.5 % to 100 % for low grade, and 0 %-65 % for high grade disease. This article focuses on the etiopathogenesis, clinical behavior, diagnosis and classification of mucinous tumors of the appendix and pseudomyxoma peritonei.
阑尾肿瘤较为罕见,但由于其临床表现不寻常且生物学行为不可预测,正确诊断至关重要。在监测、流行病学与最终结果(SEER)数据库中,黏液性肿瘤占阑尾恶性肿瘤的58%,其余为类癌。黏液性阑尾肿瘤有可能以含有或不含有肿瘤细胞的胶冻样物质形式扩散至腹膜和内脏,导致腹膜假黏液瘤(PMP)。PMP是一种具有独特生物学行为的临床实体,可源自看似良性的肿瘤,也可发展为明显恶性的肿瘤。PMP有多种分类,其中罗内特分类最为常用。2010年,世界卫生组织(WHO)提出了一种两级分类法,根据黏液、细胞学和结构特征将PMP分为低级别或高级别。根据该分类,当PMP的潜在病因是阑尾肿瘤时,它总是黏液性腺癌,而非黏液囊肿或腺瘤,不应再使用这些术语。这种分类系统有助于预测肿瘤行为和制定恰当的治疗策略。随着新生物标志物和分子遗传学改变的发现,对该疾病发病机制的认识也有所提高。除了KRAS突变和某些基因位点的杂合性缺失外,免疫组化标志物细胞角蛋白20(CK 20)、尾型同源盒转录因子2(CDX2)和黏蛋白2(MUC2)在这些肿瘤中呈阳性。正确的组织病理学分类和预测肿瘤行为需要病理学家和外科医生密切合作。细胞减灭术(CRS)和热灌注化疗(HIPEC)联合治疗的应用使低级别疾病的5年生存率为62.5%至100%,高级别疾病的5年生存率为0%至65%。本文重点探讨阑尾黏液性肿瘤和腹膜假黏液瘤的病因发病机制、临床行为、诊断及分类。